Literature DB >> 7037261

Drug metabolites in renal failure: pharmacokinetic and clinical implications.

R K Verbeeck, R A Branch, G R Wilkinson.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7037261     DOI: 10.2165/00003088-198106050-00001

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  118 in total

Review 1.  Diseases and drug protein binding.

Authors:  J P Tillement; F Lhoste; J F Giudicelli
Journal:  Clin Pharmacokinet       Date:  1978 Mar-Apr       Impact factor: 6.447

2.  The metabolism of antipyrine in patients with chronic renal failure.

Authors:  M Lichter; M Black; I M Arias
Journal:  J Pharmacol Exp Ther       Date:  1973-12       Impact factor: 4.030

3.  Relation between serum quinidine levels and renal function. Studies in normal subjects and patients with congestive failure and renal insufficiency.

Authors:  S Bellet; L R Roman; A Boza
Journal:  Am J Cardiol       Date:  1971-04       Impact factor: 2.778

4.  Acebutolol metabolite plasma concentration during chronic oral therapy.

Authors:  R A Winkle; P J Meffin; W B Ricks; D C Harrison
Journal:  Br J Clin Pharmacol       Date:  1977-10       Impact factor: 4.335

5.  Clinical pharmacokinetics of procainamide infusions in relation to acetylator phenotype.

Authors:  J J Lima; D R Conti; A L Goldfarb; W J Tilstone; L H Golden; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

6.  Comparison of the acetylation of procainamide and sulfadimidine in man.

Authors:  K Frislid; M Berg; V Hansteen; P K Lunde
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

7.  The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites.

Authors:  K J Hoffmann; C G Regårdh; M Aurell; M Ervik; L Jordö
Journal:  Clin Pharmacokinet       Date:  1980 Mar-Apr       Impact factor: 6.447

8.  Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide.

Authors:  D M Roden; S B Reele; S B Higgins; G R Wilkinson; R F Smith; J A Oates; R L Woosley
Journal:  Am J Cardiol       Date:  1980-09       Impact factor: 2.778

9.  Kinetics of salicylate elimination by anephric patients.

Authors:  D T Lowenthal; W A Briggs; G Levy
Journal:  J Clin Invest       Date:  1974-11       Impact factor: 14.808

10.  Plasma and urine concentrations of acebutolol and its acetyl metabolite in patients with renal functional impairment.

Authors:  S Munn; R R Bailey; E Begg; R Ebert; D G Ferry
Journal:  N Z Med J       Date:  1980-04-23
View more
  23 in total

1.  Pharmacokinetics of quinine in patients with chronic renal failure.

Authors:  P Rimchala; J Karbwang; K Sukontason; V Banmairuroi; P Molunto; K Na-Bangchang
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

Review 2.  Principles of pharmacotherapy: I. Pharmacodynamics.

Authors:  T J Pallasch
Journal:  Anesth Prog       Date:  1988 May-Jun

Review 3.  Clinical pharmacokinetics of beta-adrenoceptor antagonists. An update.

Authors:  J G Riddell; D W Harron; R G Shanks
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

4.  Antipyrine metabolite formation and excretion in patients with chronic renal failure.

Authors:  M W Teunissen; D Kampf; I Roots; N P Vermeulen; D D Breimer
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

Review 5.  Pharmacokinetic optimisation of the treatment of osteoarthritis.

Authors:  K J Skeith; D R Brocks
Journal:  Clin Pharmacokinet       Date:  1994-03       Impact factor: 6.447

6.  The disposition of paracetamol and the accumulation of its glucuronide and sulphate conjugates during multiple dosing in patients with chronic renal failure.

Authors:  U Martin; R M Temple; R J Winney; L F Prescott
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

7.  Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion.

Authors:  Bengt Hamrén; Hans Ericsson; Ola Samuelsson; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2008-02-21       Impact factor: 4.335

8.  Metabolism of amitriptyline in patients with chronic renal failure.

Authors:  M Sandoz; S Vandel; B Vandel; B Bonin; B Hory; Y St Hillier; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

9.  The disposition of paracetamol and its conjugates during multiple dosing in patients with end-stage renal failure maintained on haemodialysis.

Authors:  U Martin; R M Temple; R J Winney; L F Prescott
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 10.  Interpretation of drug levels in acute and chronic disease states.

Authors:  E Perucca; R Grimaldi; A Crema
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.